HPN-100
Sponsors
Amgen
Conditions
CirrhosisDrug ToxicityHealthyHepatic EncephalopathyUrea Cycle Disorders
Phase 1
A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)
CompletedNCT00977600
Start: 2005-03-31End: 2005-07-31Updated: 2024-06-20
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
CompletedNCT00986895
Start: 2006-09-30End: 2007-06-30Updated: 2024-06-20
Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100
CompletedNCT01135680
Start: 2010-05-31End: 2010-09-30Updated: 2024-06-20
Phase 2
Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders
CompletedNCT00551200
Start: 2007-10-31End: 2008-12-31Updated: 2024-07-10
Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders
CompletedNCT00947544
Start: 2010-03-31End: 2011-08-31Updated: 2024-07-11
A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
CompletedNCT00999167
Start: 2009-12-31End: 2012-04-30Updated: 2024-07-10
Phase 3
Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
CompletedNCT00947297
Start: 2009-11-30End: 2011-11-30Updated: 2024-07-10
Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders
CompletedNCT00992459
Start: 2009-10-31End: 2010-09-30Updated: 2024-07-09
Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)
CompletedNCT01347073
Start: 2011-07-31End: 2013-03-31Updated: 2024-07-11